Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Share-based Compensation (2021 - 2026)

MoonLake Immunotherapeutics' Share-based Compensation history spans 6 years, with the latest figure at $13.4 million for Q1 2026.

  • Quarterly Share-based Compensation rose 483.19% to $13.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $24.0 million through Mar 2026, up 203.52% year-over-year, with the annual reading at $12.9 million for FY2025, 77.12% up from the prior year.
  • Share-based Compensation came in at $13.4 million for Q1 2026, up from $3.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.4 million in Q1 2026 to a low of $1.4 million in Q3 2023.
  • The 5-year median for Share-based Compensation is $2.3 million (2025), against an average of $3.0 million.
  • Year-over-year, Share-based Compensation crashed 71.32% in 2022 and then skyrocketed 483.19% in 2026.
  • MoonLake Immunotherapeutics' Share-based Compensation stood at $2.6 million in 2022, then crashed by 38.17% to $1.6 million in 2023, then increased by 20.46% to $1.9 million in 2024, then soared by 85.63% to $3.6 million in 2025, then soared by 272.01% to $13.4 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Share-based Compensation are $13.4 million (Q1 2026), $3.6 million (Q4 2025), and $3.7 million (Q3 2025).